Drug intelligence / Profile preview

Shengxueyin

Development stage: Preclinical
Administration: Oral

Overview

Shengxueyin is a traditional Chinese medicine formulation reportedly used for the treatment of hematological conditions such as thrombocytopenic purpura and anemia. It is described in Chinese patent literature as a multi-ingredient herbal preparation with claimed efficacy in increasing platelet counts and improving symptoms associated with blood deficiencies. The formula typically contains several herbal components, but the precise composition may vary by manufacturer or region. There is no evidence that it is an approved pharmaceutical drug outside of China, nor does it appear to be regulated as a conventional pharmaceutical product in major international markets[7]. No specific mechanism of action has been established according to Western pharmacology.

Brand names: Shengxueyin
Other names: Shengxueyin

Beyond the preview

Go deeper on Shengxueyin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shengxueyin.

Explore the full profile